Bone Turnover Markers for use in Translational Research
Immunodiagnostic Systems Limited (referred to hereafter as IDS) offers a full panel of bone turnover markers (BTM’s) for translational research, including both bone resorption (C-terminal telopeptides (CTX-I)), bone formation markers (Procollagen type 1 propeptides (PINP)), and Osteocalcin and osteoclast markers (tartrate-resistant-acid phosphatase 5b (TRAcP5b)), adequate for cell culture, animal models, human research and routine clinical laboratories.
IDS are committed to provide highly accurate and reproducible assays for the measurement of bone turnover markers, thus ensuring reliability of results. Throughout life, old bone is constantly removed (resorption) and replaced by new bone (formation). This continual process is essential for the maintenance of healthy bone mass and micro-architecture. Accelerated bone mass resorption can occur in women in postmenopausal years.
Osteoporosis is a disease characterised by low bone density and reduced structural strength of the bone leading to increased risk of bone fracture. Osteoporosis affects approximately 30% of postmenopausal women in the US and Europe.1 Around the world, 1 in 3 women and 1 in 5 men are at risk of osteoporotic fracture.1
When addressing changes in bone turnover at the organ or organism level, monitoring tools adequately reflecting the outcome of tissue homeostasis become particularly critical. In this context, bioassays targeting the quantification of various degradation and formation products of bone matrix elements represent a useful approach.2
Changes in bone turnover can be assessed by using the comprehensive IDS bone turnover test panel. Find out more about our Bone Turnover Marker product panel by visiting the product pages below.
2. Schaller, S et al., In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005 Oct;3(5):553-80.